NEW YORK – Apton Biosystems, a Pleasanton, California-based firm developing sequencing and protein detection technology, said on Wednesday that it has raised $24 million in Series A financing.
Kern Capital led the round, joined by Casdin Capital and Khosla Ventures. Jay Kern has joined Apton's board of directors.
The firm plans to use the funding to continue development of its Super-Res sequencing and single-molecule proteomics detection systems.
"Genomics and advanced proteomics are utilized in a minority of clinical applications today, but have the potential to unlock the answers to every facet of human biology," Apton CEO John Hanna said in a statement. "This funding allows us to continue building the team and technology to address the challenges in reaching the scale necessary for routine clinical use."
Founded in 2012, Apton has designed optical systems for sequencing and protein detection. It has also received funding from Samsung Catalyst Fund and Cowen Investments.